FDA Approves Two Breakthrough Cancer Treatments for AstraZeneca
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
India’s first global CAR T-cell therapy for Non-Hodgkin’s Lymphoma launched
India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...
lupus.bmj9h
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...
Pharmabiz11h
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...